Category Archives: Delaware Stem Cells

Wilmington, Delaware, United States, July 04, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc.: The value of the global orthobiologics market was clocked at US$ 5.01 Bn in 2021. The orthobiologics marketoutlook predicts the market to rise at a CAGR of 4.7% during the forecast period, from 2022 to 2031. The global orthobiologics market is expected to attain a value surpassing US$ 7.4 Bn by 2031. Until afew years ago, orthobiologics have been a common practice in sports medicine andorthopedic surgeries. Demand analysis of orthobiologics estimates that developments in regenerative medicine, an increasing number of sports andsports-relatedinjuries, rising demand for less invasive procedures, andconstant infusion of innovative products and treatmentsare all expected to propel the global orthobiologics market.

Musculoskeletal tissue engineering and regenerative medicineresearch, however, have slowed down as a result of the COVID-19 outbreak. However,strong development potential in developing nations and a rise in demand for cutting-edge therapies are expected to create considerable prospects for companies in the growth of the orthobiologics market.

The global orthobiologics market is being driven by the increase in orthobiologics product and usage oforthopedic device. In addition to that, there is increasingincorporation of biochemistry andbiology in the treatment of soft tissue andbone injuries. Orthobiologic drugs help natural healing mechanism of the bodyto workmore quickly. They can hasten the healing of injured ligaments, tendons, andmuscles. It alsoassistsin repairing osteoarthritis damage. The materials used to develop orthobiologics are those that are normally present in the human body.

Request Brochure of Orthobiologics Market Research Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1747

Key Findings of Market Report

Request for Analysis of COVID-19 Impact on Orthobiologics Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1747

Global Orthobiologics Market: Growth Drivers

Get Exclusive PDF Sample Copy of Orthobiologics Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1747

Global Orthobiologics Market: Key Players

Some of the key market players are

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1747

Global Orthobiologics Market: Segmentation

Product Type

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reports by Transparency Market Research:

Stem Cells Market: The global stem cells market is expected to reach the value of US$ 25.68 Bn by the end of 2028.It is estimated to expand at a CAGR of 10.4% from 2021 to 2028.

Placental Stem Cell Therapy Market: The placental stem cell therapy market stood at US$ 0.5 Bn in 2019 and is expected to cross a revenue of US$ 4.4 Bn by the end of 2030.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: The global platelet rich plasma & stem cell alopecia treatment market is expected to reach a value of approximately US$ 450.5 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period.

Soft Tissue Allografts Market: The global soft tissue allografts market was valued at US$ 3.55 Bn in 2018, and is projected to reach ~ US$ 6.2 Bn by 2027, expanding at a CAGR of ~ 6.5% from 2019 to 2027.

Bone Growth Stimulators Market: The global bone growth stimulators market is anticipated to reach more than US$ 2 Bn by the end of 2031. The global market is projected to grow at a CAGR of 5.8% from 2022 to 2031.

Small Bone and Joint Orthopedic Devices Market: The global small bone and joint orthopedic devices market was valued at US$ 5.5 Bn in 2018 and is anticipated to expand at a CAGR of 6.3% from 2019 to 2027.

Metastatic Bone Disease Market: The global metastatic bone disease market was valued at US$ 12,450.0 Mn in 2017 and is anticipated to reach US$ 24,886.8 Mn by 2026, expanding at a CAGR of 8.1% from 2018 to 2026.

Bone Grafts and Substitutes Market: The global bone grafts and substitutes market is expected to cross the value of US$ 4.4 Bn by the end of 2028. It is estimated to expand at a CAGR of 4.9% from 2021 to 2028.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:sales@transparencymarketresearch.com

Read the original:
Orthobiologics Market is Predicted to Expand at a CAGR of 4.7% during the Forecast Period, notes TMR Study - GlobeNewswire

Wilmington, Delaware, United States, Transparency Market Research Inc.: Cell line development is an important technology in life sciences. Stable cell lines are used for various applications including monoclonal antibody and recombinant protein productions, gene functional studies, and drug screening

Read Report Overview - https://www.transparencymarketresearch.com/cell-line-development-market.html

Manual screening method is a traditional method used for cell line development. This method is tend to be disadvantageous as it is labor-intensive and time-consuming. Automation in tools used for cell line development is likely to replace manual methods of cell line development.

Cell line development and culturing is being rapidly adopted in areas of biological drug developments for various chronic diseases, regenerative medicines such as stem cells & cell-based therapies, recombinant protein, and other cellular entities for pharmaceuticals, diagnostics, and various other industries.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75773

Key Drivers and Opportunities of Global Cell Line Development Market

Rise in focus on research & development, owing to increase in prevalence of cancer and other chronic diseases is anticipated to drive the market. Several institutes, such as Cancer Research Institute, National Cancer Institute, Advanced Centre for Treatment, Research and Education in Cancer (Cancer Research Centre [ICRC]), and NCI Community Oncology Research Program (NCORP), are engaged in research & development for cancer diagnosis and treatment. Hence, the initiative of government and non-government organizations is likely boost the growth of the market.

Mammalian cell lines are widely used as production tools for various biologic drugs. Technological advancement in cell line development in mammalian cell culturing is likely to fuel the growth of the market. For instance, according to an article published in Pharmaceuticals (Basel), the U.S. Food and Drug Administered approved 15 novel recombinant protein therapeutics from 2005 to 2011 on an average.

Advances in bioinformatics and recombinant technologies have led to development of new cell lines for synthesis or production of essential peptides, enzymes, saccharides, and other molecules which are being used in pharmaceuticals and various other industries.

Request for Analysis of Cell Line Development Market Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75773

North America to Capture Major Share of Global Cell Line Development Market

North America is expected to account for major share of the global cell line development market due to well-established health care infrastructure and rise in government initiatives. Furthermore, adoption of innovative technologies is likely to augment the market in the region.

The cell line development market in Asia Pacific is expected to grow at a rapid pace during the forecast period, owing to increasing risk of communicable diseases, cancer, and chronic & rare diseases and surge in geriatric population. For instance, according to an article published in BioMed Central Ltd, in 2018, 2.9 million cancer deaths occurred and 4.3 million new cancer cases were recorded in China.

Key Players Operating in Global Cell Line Development Market

The global cell line development market is highly concentrated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Key players engaged in adopting new strategies are likely to drive the global cell line development market. Key players are developing new, cost-effective biologic products. This is anticipated to augment the market.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=75773

Major players operating in the global cell line development market are:

More Trending Reports by Transparency Market Research

Surgical Retractors Market: Surgical Retractors Market (Product Type: Hand-held Retractors, Self-retaining Retractors, Table-mounted Retractors, and Others; Application: Abdominal Surgeries, Cardiothoracic Surgeries, Orthopedic Surgeries, Obstetric & Gynecological Surgeries, and Others; and End User: Hospitals, Ambulatory Surgical Centers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Dental Consumables Market: Dental Consumables Market (Product - Dental Implants, Crowns and Bridges, Dental Biomaterials, Orthodontics, Endodontics, Periodontics, Retail Dental Care Essentials, and Dental Consumables) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Vascular Stents Market: Vascular Stents Market (Type: Coronary Artery Stents, Peripheral Vascular Stents, and Neurovascular Stents; Delivery Method: Balloon Expandable Stents and Self-expanding Stents; Material: Cobalt-Chromium Stent, Platinum-Chromium Stent, Nitinol Stent, Stainless Steel Stent, and Bioresorbable Polymer Stent; End User: Hospitals, Cardiac Centers, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Monopolar Electrosurgery Market: Monopolar Electrosurgery Market (Product Type - Hand Instruments, Electrosurgical Generator, Return Electrode (Single Use and Re-usable), Accessories (Footswitches and Connectors); Application - General Surgery, Gynecology Surgery, Cardiovascular Surgery, Cosmetic Surgery, Orthopedic Surgery, and Urology Surgery; End User: Hospitals, Ambulatory Surgical Centers, and Specialty Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Vertebroplasty and Kyphoplasty Market: Vertebroplasty and Kyphoplasty Market (Product - Vertebroplasty (Needles, Cement Mixing and Delivery Devices), Kyphoplasty (Needles, Balloons, Cement Mixing and Delivery Devices); End use - Hospitals, Ambulatory Surgery Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Air Bubble Detectors Market: Air Bubble Detectors Market (Product Type: Fixed Detectors and Flexible Detectors; Technology: Ultrasonic Sensors and Capacitive Sensors; Application: Dialysis & Transfusion, Cardiopulmonary Bypass, Infusion & Parenteral Infusion Pumps, Diagnostic Devices, Blood Processing Equipment, and Others; and End User: Hospitals & Healthcare Providers, Diagnostic Laboratories, and Pharmaceuticals & Biotechnology Industries) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Refurbished Medical Equipment Market: Refurbished Medical Equipment Market (Product: Medical Imaging Equipment, Operating Room Equipment, Patient Monitoring Devices, and Others; Application: Cardiology, Respiratory and Gastroenterology, Neonatal Care, Orthopedic, and Others; and End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Medical Laser Systems Market: Medical Laser Systems Market (Product Type: Gas Lasers, Solid-state Lasers, Fiber Lasers, Diode Lasers, Femtosecond Lasers, and Others; Application: Ophthalmology, Cosmetic/Dermatology, Dentistry, Cancer Therapy, Cardiovascular, and Others; and End User: Hospitals, Ambulatory Surgical Centers, and Specialized Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 2030

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

See the rest here:
Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global transplant diagnostic market was valued at US$ 730.9 Mn in 2017 and is projected to expand at a cumulative annual growth rate (CAGR) of 6.6% from 2018 to 2026 according to a new report published by Transparency Market Research (TMR) titled Transplant Diagnostic Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026 the report suggests that increase in number of cancer & blood disorder patients and rise in the demand for accurate and cost-effective transplant diagnostic systems is fueling the transplant diagnostic market between 2018 and 2026.

North America and Europe are projected to dominate the global market owing to the increase in demand for efficient and effective management of transplant diagnostic technique and high adoption rate of transplant of organs. The market in Asia Pacific is projected to expand at a prominent growth rate during the forecast period. Expansion of the market in Asia Pacific is attributed to the large base of hospital & transplant centers and research centers, rising number of geriatric population requiring kidney dialysis services, and increasing awareness regarding donation of organs among young generation in the region. The market for transplant diagnostic in Latin America is likely to expand at a moderate growth rate during the forecast period.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20225

Technological assay in transplant diagnostic is expected to fuel global market

The global transplant diagnostic market is projected to be potentially driven by the technological assay offered by various transplant diagnostic companies. Transplant diagnostic provides a wide range of features and benefits such as identification of molecules that are expressed on the cells and are involved in the immune rejection of mismatched grafts and recognition of foreign HLA Class 2 antigens, which makes it more feasible for rapid results in transplantation technique. These features help physicians and nurses to streamline the transplantation activity required for the patients in order to maintain their daily workflow efficiently and effectively.

Key players offering transplant diagnostic are developing value-added features such as real-time PCR technology, PCR-enzyme-linked immunosorbent assay, along with imaging modules, thereby reducing the overall operating cost, which in turn improves the overall effectiveness and efficiency of diagnostic practices. Companies are focusing on the development of PCR-based products and expansion of their operations and increase in their market shares. For instance, in April 2016, Siemens and Thermo Fisher Scientific entered into a partnership, allowing Siemens to integrate Thermo Fisher Scientific's real-time PCR technology in its own technology. These value-added features and advanced assay offers rapid and sensitive detection limit, helping improve the overall duration and quality of diagnostics.

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20225

Non-molecular assay is projected to be highly lucrative deployment mode

Non-molecular assays are conventional methods of transplant diagnostic. These assays are employed in developed as well as developing countries in order to detect transplant rejections. Furthermore, these technology-based transplant diagnostic are priced on perpetual license model and are highly priced. Non-molecular assays enable the user to practice antibody-based histocompatibility test that offers low-resolution typing, as compared to molecular assays, and involve culturing together of lymphocytes.

These factors are likely to propel the segment during the forecast period. These non-molecular assay-based techniques addresses specific challenges during identification of the molecules, which expresses on the cells and are involved in the immune rejection of mismatched grafts. The non-molecular assay-based techniques offer rapid results on transplantation and are cost-effective.

Solid organ transplantation application of transplant diagnostic leads the market

The report offers the detailed segmentation of the transplant diagnostic in terms of application into solid organ transplantation and stem cell transplantation. The solid organ transplantation segment is expected to account for a leading share of the market during the forecast period. The factors attributed to the higher share held by the solid organ transplantation segment includes rising incidence of cardiac surgeries, prevalence of kidney related diseases among global population, and the demand for new organs for treatment of cancer by physician and patients. Various reimbursement and Medicare benefits available for patients in treating diseases have led to the high market share held by the solid organ transplantation segment of the global market.

Request for Analysis of COVID-19 Impact on Transplant Diagnostic Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=20225

Hospital & transplant centers segment estimated to dominate the market during the forecast period

In terms of end-user, the hospital & transplant centers segment accounted for a leading share in global transplant diagnostic market. The segment is projected to gain market share by the end of 2026. It is likely to expand at a CAGR more than 7% during the forecast period. Expansion of the conventional serological technique, increasing number of medical facilities from serological assays to genome-based HLA typing for transplant diagnostics, and adoption of large number of donors organs for transplantation practices have led the hospital & transplant centers segment to hold a prominent share of the global transplant diagnostic market.

Increasing number of multinational hospital chains and high digitization budgets are likely to drive the hospital & transplant centers segment during the forecast period. High prevalence and incidence rates of bone injuries, kidney failures, and increase in number of cases of cancer and blood disorder diseases in the global population have led to an increase in patient flow to hospital & transplant centers. These factors are expected to fuel the hospital & transplant centers segment between 2018 and 2026.

Asia Pacific represents potential business development opportunity

North America and Europe accounted for a key share of global transplant diagnostic market in 2017. They are likely to gain market share by the end of 2026. High rate of adoption of transplantation technique for cancer treatment, high submission of healthcare budgets, and government initiatives to promote the donation of organs have contributed to the leading share held by these region in the global transplant diagnostic market. Asia Pacific is projected to be a highly attractive market for transplant diagnostic, and is likely to exhibit a prominent attractiveness index, during the forecast period.

The market in Asia Pacific is projected to expand at a high CAGR of more than 7% during the forecast period. This is due to large number of hospital and transplant centers in emerging economies such as India and China as well as increase in the demand for serological technique-based assays due to their affordability, particularly in developing countries such as China, India, and Malaysia. The market in Latin America is anticipated to expand at a moderate growth rate during the forecast period.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=20225

Key trend of research and development among the leading players to increase geographic presence has been observed in last few years

The report also provides profiles of leading players operating in the global transplant diagnostic market. Bio-Rad Laboratories, Inc., Qiagen N.V., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., and Becton, Dickinson and Company are a few leading players operating in the global transplant diagnostic market, which account for significant market share. Companies operating in the transplant diagnostic industry are emphasizing on increasing their geographic presence by means of strategic acquisition and collaboration with leading players in respective domains and geography.

In July 2017, Thermo Fisher Scientific acquired Linkage Biosciences. Linkage Biosciences is presently a part of Thermo Fisher's transplant diagnostics business. Through this acquisition, Thermo Fisher currently provides services to more than 1,000 transplant centers in over 60 countries. Other prominent players operating in the global transplant diagnostic include Ortho Clinical Diagnostics (a part of Carlyle Group), Immucor, Inc., Illumina, Inc., Siemens Healthineers (Siemens AG), and Agilent Technologies .

More Trending Reports by Transparency Market Research

Dry Eye Disease Treatment Market: Dry Eye Disease Treatment Market (Product: Artificial Tears, Anti-inflammatory, Punctal Plugs, Secretagogue, and Others; Disease: Evaporative Dry Eye Syndrome and Aqueous Dry Eye Syndrome; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Alcoholic Hepatitis Therapeutics Market: Alcoholic Hepatitis Therapeutics Market (Treatment: Corticosteroids, Hemorrheologic Agents, Anabolic Steroids, and Others; Application: Mild and Severe/Chronic; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Atipamezole Market: Atipamezole Market (Application: Anti-sedative and Antitoxic [Off-label Use]; Route of Administration: Intramuscular, Intravenous, and Others; Animal Type: Dogs, Cats, and Others; and Distribution Channel: Veterinary Hospitals, Retail Pharmacies, and Online Pharmacies) - Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Anthelmintic Drugs Market: Anthelmintic Drugs Market (Drug Class: Benzimidazoles, Piperazine, and Others; Route of Administration: Oral and Injectable; Application: Human and Animal; Target Pathogen: Ascaris Lumbricoides [Roundworm], Trichuris Trichiura [Whipworm], Enterobius Vermicularis [Pinworm], Ancylostoma Duodenale [Hookworm], and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Veterinary Pharmacies, and Veterinary Hospitals & Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Mercury Poisoning Treatment Market: Mercury Poisoning Treatment Market (Drug: Chelating Agents, Combination Therapy with Chelating Agents, and Plasma Exchange Hemodialysis Plasmapheresis; Type: Acute Mercury Poisoning and Chronic Mercury Poisoning; Treatment Type: Supportive Treatment and Antidotal Treatment; Form: Inorganic Mercury, Elemental Mercury, and Organic Mercury; Route of Administration: Injectable and Oral; and Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Addiction Treatment Market: Addiction Treatment Market (Treatment Type: Alcohol Addiction Treatment, Tobacco/Nicotine Addiction Treatment, Opioid Addiction Treatment, and Other Substances Addiction Treatment; Drug Type: Bupropion, Varenicline, Acamprosate, Disulfiram, Naltrexone, Methadone, Buprenorphine, Nicotine Replacement Products, and Others; Treatment Center: Outpatient Treatment Centers, Residential Treatment Centers, and Inpatient Treatment Centers; and Distribution Channel: Hospitals Pharmacies, Medical Stores, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Human Papillomavirus and Cytomegalovirus Therapeutics Market: Human Papillomavirus and Cytomegalovirus Therapeutics Market (Drug Class: Human Papillomavirus Therapeutics and CMV Therapeutics [Ganciclovir/Valganciclovir, Foscavir {Foscarnet}, Cidofovir {Vistide}, Letermovir {Prevymis}, and Others]; Application: Human Papillomavirus Therapeutics and CMV Therapeutics; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Hydrocortisone Market: Hydrocortisone Market (Indication: Adrenocortical Insufficiency, Adrenergic Syndrome, High Blood Calcium, Thyroiditis, Rheumatoid Arthritis, Dermatitis, Asthma and Chronic Obstructive Pulmonary Disease [COPD], and Others; Route of Administration: Parenteral, Oral, Topical, and Rectal; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 2028

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

See the article here:
Transplant Diagnostic Market: Increase in Number of Cancer & Blood Disorder Patients to Drive the Market - BioSpace

Microscopy Devices Market Outlook 2028

Analysts Viewpoint on Microscopy Devices Market Scenario

Companies in the global microscopy devices market should accelerate their product development and unlock revenue opportunities to obtain competitive benefits. Market stakeholders are extending their services arms to gain competitive edge in the healthcare sector. Increasing incidences of diseases and rising applications of microscopic devices are driving the global market. Market contributors in the global microscopy devices market should focus on the production of cost-efficient microscopy devices. Rising prices of electron microscopes and scanning probe microscopes hamper the growth of the global microscopy devices market.

Request Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=226

Impact of COVID-19 on Global Microscopy Devices Market

With significant impact on the global economy and businesses, the coronavirus pandemic has put intense pressure on medical & healthcare systems. The global microscopy devices market is negatively affected due to the coronavirus pandemic. Shortage of raw materials required for microscopy devices and disrupted supply chain have hampered the growth of the global microscopy devices market. However, due to significant efforts taken by healthcare providers and market stakeholders, the global microscopy devices market is expected to show potential growth opportunities in the upcoming years.

The increasing demand for integrated microscopes in research laboratories, hospitals, and diagnostic laboratories is driving the global market. Manufacturers operating in the global microscopy devices are focusing on product innovations due to growing demand at the global level. In addition, microscopic devices are increasingly being used in nanotechnology and semiconductor industries.

Growth and Advancement in Semiconductor Industry to Boost Market Growth

The global microscopy devices market is projected to witness value-grab opportunities in the near future, owing to increasing investments in research laboratories, healthcare advancement, and rising prevalence of diseases across the globe. With rapid advancements in technology, research & development activities are also increasing in developing countries. Moreover, application of microscopes in the semiconductor industry is rising. These devices are widely being used in the semiconductor industry for research & development, quality checking, monitoring, quality control, analysis of process development, etc.

The increasing popularity of nanotechnology,quantum dots, and optoelectronics boosts the demand for microscopic devices.

Increasing Demand Due to Rising Applications in Life Sciences

Manufacturers operating in the global microscopy devices market are increasing their production portfolio to fulfill the demand from healthcare and life sciences sectors. Microscopes are popularly used in the field of cellular biology for stem cells and cancer cells research. Growth and advancement in the field of biomedical engineering boost the demand for microscopy devices. Due to various benefits and unique properties of these microscopic devices, many diagnostic laboratories, ambulatory surgery centers, and physicians make use of them for research and analysis. Fluorescence microscopes, electron microscopes, microscopy accessories, and optical microscopes are extremely beneficial for the biomedical and biological research applications. This growth is expected to continue in the foreseeable future, which, in turn, drives the global microscopy devices market.

Expanding Contact Research Organizations (CROs) Drives Market Growth

Manufacturers operating in the global microscopy devices market are bolstering their research & development capabilities to experiment with new technologies and applications. Microscopy devices companies are establishing their foot in outsourcing R&D activities from various contact research organizations to stay ahead of the competition and generate more revenue opportunities.

Increasing government expenditure on healthcare and research & development activities strengthens the scope and expansion of contact research organizations. Many CROs provide clinical-study and clinical-trial support for different medical devices such as microscopy devices.

In addition, emerging contract research organizations in developing nations are attracting new players in the global microscopy devices market. Several pharmaceutical and biotechnology companies are outsourcing their R&D in order to focus on core business segments, and reduce manpower and other expenditure. This has encouraged CROs to expand their field of expertise and solutions, enter diverse research segments, and provide a range of R&D solutions to the companies.

Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=226

Opportunities for Prominent Market Players in North America

The increasing presence of highly developed research institutes and laboratories in North America is a major factor driving the microscopy devices market in the region. Investments on R&D, availability of advanced microscopy devices by top market leaders, and rising focus on nanotechnology are some of the factors positively contributing to the market growth in North America.

Growing adoption of technologically advanced microscopy devices such as electron microscopy, scanning probe microscopy, etc., and advancements in life sciences and pharmaceutical industries further boost market growth. However, high cost of advanced microscopy devices and high customs duty & excise tax are factors affecting the growth of the market in North America. Top players in the microscopy devices market are focusing on various strategies to strengthen their market presence.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: [emailprotected]sparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Biospace Links

https://www.biospace.com/article/inactivated-vaccines-market-rise-in-awareness-among-people-about-immunization-to-drive-the-market/

Read the original:
Microscopy Devices Market Competitive Insights and Precise Outlook 2021-2028 Industrial IT - Industrial IT

Wilmington, Delaware: Substantial developments in neoantigen targeted therapies have helped in adoption of personalized treatment approaches. These therapies have shown a noteworthy result in the treatment of cancer in several cases. Neoantigen-targeted therapies help in curing cancer by improving the response of immune system and generating new immune responses.

Read Report Overview - https://www.transparencymarketresearch.com/neoantigen-targeted-therapies-market.html

At present, there are several therapies that are under investigation by researchers along with several checkpoint inhibitors.

An upcoming report on the neoantigen targeted therapies market is expected to offer an in-depth analysis of key industry aspects. The report highlights the capabilities of various stakeholders in the market and latest strategies adopted by them. The report is recommended to readers who are associated with the neoantigen targeted therapies market directly and indirectly.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=71304

Neoantigen Targeted Therapies Market: Notable Developments and Competitive Landscape

The vendor landscape of the neoantigen targeted therapies market is moderately consolidated with a few players enjoying the majority of market share. Some of the prominent players operating in the neoantigen targeted market are Bavarian Nordic, Gradalis, Genocea Biosciences, Immunicum, Immunovative Therapies, and Iovance Biotherapeutics.

These players are expected to indulge in collaboration and geographical expansion of their business. Further, giant players are increasing their focus on the advanced research and development activity.

For example, in May 19, Genocia, a key player in the neoantigen targeted therapies market, collaborated with a Iovance to research on the tumor-infiltrating lymphocytes(TIL). This will help Genocia explore and develop neoantigen for TIL. Such developments in the neoantigen targeted therapies market are expected to offer several lucrative prospect for the growth of the global neoantigen targeted therapies market.

Request for Analysis of COVID-19 Impact on Neoantigen Targeted Therapies Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=71304

Neoantigen Targeted Therapies Market: Key Trends

Neoantigen targeted therapies are an advanced form of dealing with the several immunity disorder and cancer. The therapy improves the response of the bodys immune system and promotes long term growth of activated T cells.

The incompetency of the other cancer treatment therapies such as chemotherapy on the cancer patients calls for more effective treatment. This opens several lucrative opportunities for the growth of the neoantigen targeted therapies market in the coming years.

Along with this, factors such as prevalence of cancer and rise in geriatric population across the globe are expected to fuel the neoantigen targeted therapies market. This is because the immunity system of the geriatric people is weak and their body lack desired energy required to resist chemo drugs. In such situation, neoantigen targeted therapies are possible solution for the treatment of the cancer.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=71304

Despite several opportunities, neoantigen targeted therapies are at present at its nascent stage. Hence there is scarcity of resource in the market.

Nonetheless, increasing popularity and growing consumer awareness are expected to boost the prospects of the neoantigen targeted therapies market in the coming few years.

Pre Book Neoantigen Targeted Therapies Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=71304&ltype=S

Neoantigen Targeted Therapies Market: Regional Outlook

On the basis of region, North America is anticipated to lead in terms of market share during the forecast period. This is mainly because of presence of maximum consumer pool in the region. In addition to this, factors such as well-developed healthcare infrastructure, early adoption of advanced technology, and favorable government reimbursement plan are expected to play a significant role in the growth of the global neoantigen targeted therapies market.

More Trending Reports by Transparency Market Research:

Particle Therapy Market: Increase in adoption of particle therapy along with advantages such as high precision, shorter treatment duration, and lower side-effects compared to conventional photon therapies using X-rays are expected to drive the global particle therapy market from 2022 to 2031

Radiation Therapy Market: Increase in incidence and prevalence rates of cancer in developing and developed countries across the world, rise in technological advancements, and surge in health care spending are projected to boost the global radiation therapy market during the forecast period.

Combination Antibody Therapy Market: The global combination antibody therapy market has undergone revolutionary progress in the past few years owing to continued focus on development of targeted cancer therapies that lead to fewer side effects.

Canine Stem Cell Therapy Market: The global canine stem cell therapy market has seen vast developments in the past few years in terms of the technology available for obtaining, preserving, and using stem cells.

Erectile Dysfunction Shockwave Therapy Market: The global erectile dysfunction shockwave therapy market is driven by high prevalence and rise in incidence rate of erectile dysfunction across the globe.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Rohit BhiseyTransparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

See more here:
Neoantigen Targeted Therapies Market Analysis and Opportunity Assessment up to 2027 - BioSpace

Biochemist studies when enzymes in our cells go wrong and misbehave in human disease.

University of Delaware researcher awarded NIH grant to study why eraser enzymes go wrong and lead to cancer.

University of Delaware biochemist Jeff Mugridge is trying to figure out how so-called mRNA eraser enzymes work in our cells, why those erasers can sometimes misbehave and lead to cancer, and how science can pave the way for possible solutions to this problem.

Ribonucleic acid (RNA) is a single-stranded molecule that is copied from the DNA in our bodies. Messenger RNA (mRNA) molecules carry the instruction code that tells our cells how to do everything they need to survive, such as when, where and how to make proteins or enzymes.

One of the many ways the cells in our bodies control mRNA molecules is to decorate them with different chemical groups that either subtly or drastically change the way that messages are conveyed.

Mugridge, assistant professor of chemistry and biochemistry, was recently awarded $1,956,466 from the National Institutes of Health (NIH) to study specific enzymes that can act like erasers and remove critical chemical groups, called methyl groups, found on mRNA molecules.

With hard-to-treat cancers like glioblastoma, sometimes these methyl eraser enzymes are overexpressed in cancer cells meaning too many eraser enzymes are working at once. This can cause mRNA molecules to lack important information, which can change the messages they deliver in a way that leads to cancer progression and tumor growth.

University of Delaware Assistant Professor Jeff Mugridge is studying eraser enzymes that can remove important chemical groups from mRNA, the molecules in our bodies that carry instructions and code to tell our cells how to function. The work has the potential to inform treatment options for various human diseases where these eraser enzymes misbehave. Credit: Photo by Evan Krape

Little is known about how these eraser enzymes decide which methyl groups to eliminate or keep, how often they erase methyl groups in healthy cells or why they misbehave in some human diseases.

Along with two doctoral students working in his lab, Mugridge is specifically looking at a class of eraser enzymes called RNA demethylases. Demethylases remove methyl groups on RNA that play important roles in gene expression and the progression of cancers like glioblastoma or acute myeloid leukemia.

RNA methylation is a biochemical process that can act like a switch and turn certain activities on or off in our cells. It is known to be important for producing properly shaped RNA molecules, synthesizing proteins and determining the lifespan of RNA molecules in the cell, among other things. Methyl modifications on mRNA also play a role in cell fate decisions and the way embryonic stem cells are differentiated during development.

Scientists have recently identified a few RNA methyl modification erasers, which has raised the intriguing possibility that these methyl groups can be both written and erased from an mRNA transcript, Mugridge said. But how these eraser enzymes recognize and choose which specific methyl groups to remove out of the thousands that are found on RNA, and how frequently they do this, remains poorly understood.

Does it happen all the time, or is it a rare event? Does it only happen in disease or in specific cell types? These are some of the questions Mugridge and his team plan to answer. The research team also will explore how proteins and other cofactors, such as vitamin C, regulate demethylase activity in the cell.

Long-term, if we have a high-resolution picture of how these demethylase enzymes work, then we can begin to understand how each eraser is linked to different human diseases and disease progression, said Mugridge. This will give us better information about which of these enzymes to target for inhibition and how, for example, to slow down tumor progression in cancer.

For instance, in glioblastoma an eraser enzyme known as FTO is overexpressed, meaning the glioblastoma cells make much more of it compared to normal cells. This leads to a lot of methyl-erasing activity on RNA in those cancer cells, which seems to be important for cancer progression. Research has shown that when FTO is inhibited with a drug, it slows down cancer progression in glioblastoma. However, therapeutics that can selectively and effectively target RNA demethylase enzymes to treat cancers have eluded scientists.

If Mugridge and his team can figure out the molecular details of how these demethylase enzymes work and how the cell controls their functions, they could look for ways to manipulate which methyl groups get erased from RNA and pave the way for therapeutics that help correct misbehaving eraser enzymes in disease.

If we understood how the RNA molecule binds, exactly where it binds on the protein surface and how it interacts with specific amino acids that make up the protein, we might be able to fill in the missing pieces of the puzzle and then develop tools to monitor or influence this erasing activity in cells, he said.

In Brown Laboratory, Mugridge and his students produce proteins in bacterial cells and then purify and isolate the specific RNA demethylases of interest. Brittany Shimanski, a doctoral student from the Chemistry-Biology Interface program, is using these purified enzymes to conduct biochemistry and structural biology studies to better understand how the eraser enzymes function and select their targets.

Mugridge explained that if the team can grow crystals of the proteins in complex with the modified RNA groups that they act on, they can take them to a national lab and shoot them with high-intensity X-rays to get 3D images of the enzymes shape, including information about where all the atoms are located and how the enzymes bind to the methylated RNA that they are going to erase.

This atomic-scale structural biology information can provide critical insights into how an enzyme works and will also inform doctoral student Luke Calzinis work to understand how these eraser enzymes are controlled by different proteins or small-molecule co-factors, such as vitamin C, that can change their activity or selectivity.

The work could give scientists new ways to ask specific questions in cells, too.

We feel like were working on an important problem that could be significant for understanding how different diseases work and how they are impacted by changes in RNA methylation, said Mugridge.

The new five-year project is funded through NIHs Maximizing Investigators Research Award (MIRA) program.

Continue reading here:
Why Eraser Enzymes Go Wrong and Lead to Cancer - SciTechDaily

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL

- Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (EU), addressing an urgent unmet medical need

- In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory DLBCL1,2,3

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / August 26, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (INCY) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). The EC Decision follows the positive opinion received from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in June 2021 recommending the conditional marketing authorization of Minjuvi.

"People living with relapsed or refractory DLBCL in the EU have historically had limited treatment options and a poor prognosis. However, with the EC's approval of Minjuvi, eligible patients now have a new and much needed treatment option," said Herv Hoppenot, Chief Executive Officer, Incyte. "We will now focus our efforts on working with individual countries in Europe to provide people access to this new treatment."

"The approval of Minjuvi is a crucial milestone for patients with relapsed or refractory DLBCL in Europe, "said Jean-Paul Kress, M.D., Chief Executive Officer, MorphoSys. "DLBCL is the most common type of non-Hodgkin lymphoma in adults and Minjuvi addresses an urgent unmet medical need for the 30-40% of people who do not respond to or relapse after initial therapy."

The conditional approval is based on the results from the L-MIND study evaluating the safety and efficacy of tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant (ASCT). The results showed best objective response rate (ORR) of 56.8% (primary endpoint), including a complete response (CR) rate of 39.5% and a partial response rate (PR) of 17.3%, as assessed by an independent review committee. The median duration of response (mDOR) was 43.9 months after a minimum follow up of 35 months (secondary endpoint). Tafasitamab together with lenalidomide was shown to provide a clinically meaningful response and the side effects were manageable. Warnings and precautions for tafasitamab include infusion-related reactions, myelosuppression, including neutropenia and thrombocytopenia, infections and tumour lysis syndrome.

"The data from the L-MIND study demonstrate the potential benefits, including long duration of response, that tafasitamab may have for eligible DLBCL patients," said Professor Pier Luigi Zinzani M.D., Ph.D., Head of Lymphoma Group at University of Bologna. "It is encouraging to see new treatments become available for these patients, especially given the historical lack of treatment options in this area."

Incyte and MorphoSys share global development rights to tafasitamab; Incyte has exclusive commercialization rights to tafasitamab outside the United States. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S., and is marketed by Incyte under the brand name Minjuvi in the EU.

About Diffuse Large B-Cell Lymphoma

DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide, comprising 40% of all cases4 , and is characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs5 . It is an aggressive disease with about one in three patients not responding to initial therapy or relapsing thereafter6 . In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory DLBCL7,8,9 .

About L-MIND

The L-MIND trial is a single arm, open-label Phase 2 study (NCT02399085) investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have had at least one, but no more than three prior lines of therapy, including an anti-CD20 targeting therapy (e.g., rituximab), who are not eligible for high-dose chemotherapy (HCD) or autologous stem cell transplant (ASCT). The study's primary endpoint is overall response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). The study reached its primary completion in May 2019.

For more information about L-MIND, visit https://clinicaltrials.gov/ct2/show/NCT02399085 .

About Minjuvi (tafasitamab) Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

In the United States, Monjuvi(tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In Europe, Minjuvi (tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.

Minjuvi and Monjuvi are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S., and marketed by Incyte under the brand name Minjuvi in the EU.

XmAb is a registered trademark of Xencor, Inc.

Safety Information from the EU Summary of Product Characteristics (SmPC)

Infusion-related reactions may occur and have been reported more frequently during the first infusion. Patients should be monitored closely throughout the infusion and should be advised to contact their healthcare professionals if they experience signs and symptoms of infusion related reactions including fever, chills, rash or breathing problems within 24 hours of infusion. A premedication should be administered to patients prior to starting tafasitamab infusion. Based on the severity of the infusion-related reaction, tafasitamab infusion should be interrupted or discontinued and appropriate medical management should be instituted.

Fatal and serious infections, including opportunistic infections, occurred in patients during treatment with Minjuvi.

Minjuvi should be administered to patients with an active infection only if the infection is treated appropriately and well controlled. Patients with a history of recurring or chronic infections may be at increased risk of infection and should be monitored appropriately. Patients should be advised to contact their healthcare professionals if fever or other evidence of potential infection, such as chills, cough or pain on urination, develops.

Treatment with Minjuvi in combination with lenalidomide should not be initiated in female patients unless pregnancy has been excluded.

The most common adverse reactions were infections, neutropenia, asthenia, anemia, diarrhea, thrombocytopenia, cough, oedema peripheral, pyrexia and decreased appetite.

Minjuvi may cause serious adverse reactions. The most common serious adverse reactions were infection, including pneumonia and febrile neutropenia.

Treatment with tafasitamab can cause serious or severe myelosuppression including neutropenia, thrombocytopenia and anemia. Complete blood counts should be monitored throughout treatment and prior to administration of each treatment cycle.

About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies which are developed by partners in different areas of unmet medical need. In 2017, Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit http://www.morphosys.com or http://www.morphosys-us.com.

Tremfya is a registered trademark of Janssen Biotech, Inc.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

MorphoSys Forward-looking Statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

Incyte Forward-looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company's expectations relating to the use of tafasitamab for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the Company's ongoing clinical development program for tafasitamab, and its DLBCL program generally, contain predictions, estimates, and other forward-looking statements.

These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company's clinical trials, supply chain, and other third-party providers and development and discovery operations; determinations made by the European Commission and other regulatory authorities; the Company's dependence on its relationships with its collaboration partners; the efficacy or safety of the Company's products and the products of the Company's collaboration partners; the acceptance of the Company's products and the products of the Company's collaboration partners in the marketplace; market competition; sales, marketing, manufacturing, and distribution requirements; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.

# # #

For more information, please contact:

MorphoSys Media contacts: Thomas BiegiTel.: +49 (0)89 / 89927 26079Thomas.Biegi@morphosys.com

Jeanette BressiTel: +1 617-404-7816jeanette.bressi@morphosys.com

Investor Contact: Dr. Julia NeugebauerTel: +49 (0)89 / 899 27 179julia.neugebauer@morphosys.com

Myles CloustonTel: +1-857-772-0240myles.clouston@morphosys.com

Incyte Media: Ela ZawislakTel: + 41 21 581 5200ezawislak@incyte.com

Catalina LovemanTel: + 1 302 498 6171cloveman@incyte.com

Investors: Christine ChiouTel: +1 302 498 5914cchiou@incyte.com

References

1DRG Epidemiology data.2Kantar Market Research (TPP testing 2018).3Friedberg, Jonathan W. Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011:498-505. doi: 10.1182/asheducation-2011.1.498.4Cancer Research UK. Diffuse large B cell lymphoma. Available at https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/diffuse-large-B-cell-lymphoma. Accessed: May 2021.5Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:209-16. doi.org/10.1016/j.beha.2018.07.014.6Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253-265. doi.org/10.3747/co.26.5421.7DRG Epidemiology data.8Kantar Market Research (TPP testing 2018).9Friedberg, Jonathan W. Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011:498-505. doi: 10.1182/asheducation-2011.1.498.

SOURCE: MorphoSys AG

View source version on accesswire.com: https://www.accesswire.com/661575/MorphoSys-and-Incyte-Announce-the-European-Commission-Approval-of-MinjuviR-tafasitamab-in-Combination-with-Lenalidomide-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma

Visit link:
MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of...

WILMINGTON, Del. & PLANEGG, Germany & MUNICH--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). The EC decision follows the positive opinion received from the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) in June 2021 recommending the conditional marketing authorization of Minjuvi.

People living with relapsed or refractory DLBCL in the EU, have historically had limited treatment options and a poor prognosis. However, with the ECs approval of Minjuvi, eligible patients now have a new and much needed treatment option, said Herv Hoppenot, Chief Executive Officer, Incyte. We will now focus our efforts on working with individual countries in Europe to provide people access to this new treatment.

The approval of Minjuvi is a crucial milestone for patients with relapsed or refractory DLBCL in Europe, said Jean-Paul Kress, M.D., Chief Executive Officer, MorphoSys. DLBCL is the most common type of non-Hodgkin lymphoma in adults and Minjuvi addresses an urgent unmet medical need for the 30-40% of people who do not respond to or relapse, after initial therapy.

The conditional approval is based on the results from the L-MIND study evaluating the safety and efficacy of Minjuvi in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant (ASCT). The results showed best objective response rate (ORR) of 56.8% (primary endpoint), including a complete response (CR) rate of 39.5% and a partial response rate (PR) of 17.3%, as assessed by an independent review committee. The median duration of response (mDOR) was 43.9 months after a minimum follow up of 35 months (secondary endpoint). Minjuvi together with lenalidomide was shown to provide a clinically meaningful response and the side effects were manageable. Warnings and precautions for Minjuvi include infusion-related reactions, myelosuppression, including neutropenia and thrombocytopenia, infections and tumour lysis syndrome.

The data from the L-MIND study demonstrate the potential benefits, including long duration of response, that tafasitamab may have for eligible DLBCL patients, said Professor Pier Luigi Zinzani M.D., Ph.D., Head of the Lymphoma Group at University of Bologna. It is encouraging to see new treatments become available for these patients, especially given the historical lack of treatment options in this area.

Incyte and MorphoSys share global development rights to tafasitamab; Incyte has exclusive commercialization rights to tafasitamab outside the United States. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S., and is marketed by Incyte under the brand name Minjuvi in the EU.

About Diffuse Large B-Cell LymphomaDLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide, comprising 40% of all cases4, and is characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs5. It is an aggressive disease with about one in three patients not responding to initial therapy or relapsing thereafter6. In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory DLBCL7,8,9.

About L-MINDThe L-MIND trial is a single arm, open-label Phase 2 study (NCT02399085) investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have had at least one, but no more than three prior lines of therapy, including an anti-CD20 targeting therapy (e.g., rituximab), who are not eligible for high-dose chemotherapy (HDC) or autologous stem cell transplant (ASCT). The studys primary endpoint is overall response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). The study reached its primary completion in May 2019.

For more information about L-MIND, visit https://clinicaltrials.gov/ct2/show/NCT02399085.

About Minjuvi (tafasitamab)Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

In the United States, Monjuvi (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In Europe, Minjuvi (tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.

Minjuvi and Monjuvi are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S., and marketed by Incyte under the brand name Minjuvi in the EU.

XmAb is a registered trademark of Xencor, Inc.

Safety Information from the EU Summary of Product Characteristics (SmPC)Infusion-related reactions may occur and have been reported more frequently during the first infusion. Patients should be monitored closely throughout the infusion and should be advised to contact their healthcare professionals if they experience signs and symptoms of infusion related reactions including fever, chills, rash or breathing problems within 24 hours of infusion. A premedication should be administered to patients prior to starting tafasitamab infusion. Based on the severity of the infusion-related reaction, tafasitamab infusion should be interrupted or discontinued and appropriate medical management should be instituted.

Fatal and serious infections, including opportunistic infections, occurred in patients during treatment with Minjuvi.

Minjuvi should be administered to patients with an active infection only if the infection is treated appropriately and well controlled. Patients with a history of recurring or chronic infections may be at increased risk of infection and should be monitored appropriately. Patients should be advised to contact their healthcare professionals if fever or other evidence of potential infection, such as chills, cough or pain on urination, develops.

Treatment with Minjuvi in combination with lenalidomide should not be initiated in female patients unless pregnancy has been excluded.

The most common adverse reactions were infections, neutropenia, asthenia, anemia, diarrhea, thrombocytopenia, cough, oedema peripheral, pyrexia and decreased appetite.

Minjuvi may cause serious adverse reactions. The most common serious adverse reactions were infection, including pneumonia and febrile neutropenia.

Treatment with tafasitamab can cause serious or severe myelosuppression including neutropenia, thrombocytopenia and anemia. Complete blood counts should be monitored throughout treatment and prior to administration of each treatment cycle.

About IncyteIncyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

About MorphoSysMorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies which are developed by partners in different areas of unmet medical need. In 2017, Tremfya (guselkumab) developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis became the first drug based on MorphoSys antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of the companys proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit http://www.morphosys.com or http://www.morphosys-us.com.

Tremfya is a registered trademark of Janssen Biotech, Inc.

Incyte Forward-looking StatementsExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Companys expectations relating to the use of tafasitamab for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the Companys ongoing clinical development program for tafasitamab, and its DLBCL program generally, contain predictions, estimates, and other forward-looking statements.

These forward-looking statements are based on the Companys current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Companys clinical trials, supply chain, and other third-party providers and development and discovery operations; determinations made by the European Commission and other regulatory authorities; the Companys dependence on its relationships with its collaboration partners; the efficacy or safety of the Companys products and the products of the Companys collaboration partners; the acceptance of the Companys products and the products of the Companys collaboration partners in the marketplace; market competition; sales, marketing, manufacturing, and distribution requirements; and other risks detailed from time to time in the Companys reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.

MorphoSys Forward-looking StatementsThis communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

_____________________1 DRG Epidemiology data.2 Kantar Market Research (TPP testing 2018).3 Friedberg, Jonathan W. Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011:498-505. doi: 10.1182/asheducation-2011.1.498.4 Cancer Research UK. Diffuse large B cell lymphoma. Available at https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/diffuse-large-B-cell-lymphoma. Accessed: May 2021.5 Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:20916. doi.org/10.1016/j.beha.2018.07.014.6 Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253265. doi.org/10.3747/co.26.5421.7 DRG Epidemiology data.8 Kantar Market Research (TPP testing 2018).9 Friedberg, Jonathan W. Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011:498-505. doi: 10.1182/asheducation-2011.1.498.

Originally posted here:
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults...

Rock snot, an invasive aquatic alga, has been discovered in another Pennsylvania stream.

According to the Pennsylvania Fish and Boat Commission, Didymospheria geminata has been confirmed in Quemahoning Creek in Somerset County.

The algae has been dubbed rock snot because of its appearance when wet. When squeezed dry, the tan to greenish beige alga feels like moist cotton or wool.

Didymo does not present a public health hazard, but it can cause ecological damage by smothering other organisms which also live on the riverbed and support the food web for the resident fish community.

In response to the discovery, the commission and the Pennsylvania Department of Environmental Protection have reminded anglers and boaters that cleaning their gear is the easiest, most effective means to prevent its spread to other waters.

We may not be able to eliminate didymo from infected waterways, but there are things we can do to slow or prevent its spread to other waters, said Heather Smiles, chief of the commissions Division of Environmental Services.

Didymo cells can easily be carried downstream and can be picked up by any items or equipment in contact with infected water including fishing tackle, waders, recreational equipment, boats and trailers.

It takes just one live didymo cell to start a new colony of the alga.

The commission urges anglers and boaters to clean their gear before leaving a water body and allow it to dry completely before entering another water. After equipment is dry to the touch, allow to dry another 48 hours.

Thick and dense material such as life jackets or felt-soled wading gear will hold moisture longer, take longer to dry and can be more difficult to clean.

Soaking equipment in hot water containing dishwashing detergent (2 cups of detergent for every 2.5 gallons of water) for 20 minutes or more also will kill didymo. If hot water is not available, a commercial hot-water car wash also makes a good location to wash boats, motors and trailers.

At the other end of the temperature range, freezing items solid for at least 24 hours is effective.

If cleaning, drying or freezing is not practical, the commission suggests that the equipments use be limited to a single waterway.

The section of Quemahoning Creek where the alga was found provides fishing opportunities for stocked trout as well as warm-water and cool-water fish. The commission annually stocks fingerling brown and rainbow trout.

Since 2007 didymo has been detected in the West Branch and main stem of the Delaware River, Dyberry Creek in Wayne County, Youghiogheny River watershed in Fayette County and Pine Creek in Lycoming County.

Question about nature or the outdoors? Contact Marcus Schneck at mschneck@pennlive.com.

See the article here:
Rock snot discovered in another Pennsylvania waterway - pennlive.com

Bone marrow and stem cell transplants can be life-saving for people with blood cancers, solid tumors and some non-cancerous blood disorders. The Helen F. Graham Cancer Center & Research Institutes Bone Marrow Transplant Unit at Christiana Hospital offers todays most advanced and sophisticated techniques for patients who need peripheral blood stem cells (those that mature into red or white blood cells, or platelets) or bone-marrow transplants, including the newest, low-dose chemotherapy mini transplants. Transplants may be autologous (self-donated) or allogeneic (from a related or unrelated donor).

The hematologists/oncologists who specialize in bone-marrow and stem-cell therapy are part of a multidisciplinary team of experts ready to assist you and your family as you face the challenges of recovery. This team may include members of the Lymphoma Multidisciplinary Center who meet regularly at the Helen F. Graham Cancer Center & Research Institute.

As a candidate for bone marrow or stem cell transplantation, you will be assisted by a nurse navigatoran oncology-certified or masters prepared oncology nursewho will be on hand to answer your questions throughout your entire treatment. Your nurse navigator will work closely with the members of your treatment team to help you get the care and support services you need, both in and out of the hospital.

Your evaluation and treatment team may include the following:

Together, these specialists, in consultation with your primary-care doctor, will work with you to create the most appropriate and effective plan of treatment for your blood disorder.

New techniques for stimulating stem cells and the use of peripheral blood stem cells have led to shorter treatment times and better results for many patients. Similarly, low-dose, immunosuppressive chemotherapy and radiation prior to transplant has become a viable option, especially for older patients.

Participation in clinical research studies such as those sponsored by the National Cancer Institutes Community Clinical Oncology Program, particularly in the Cancer and Leukemia Group B, as well as in other national and local studies, offers access to the very latest treatment protocols. A research nurse will meet with you to discuss potential participation in a clinical treatment study.

We participate in the donor-matching program and will tailor your transplant to your body and your disease. Membership in the National Marrow Donor Program enables searches on a national and international level to locate potential bone-marrow donors who may be unrelated but whose tissue is the right match for you. We also participate in the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry.

The Bone Marrow Transplant Unit is one of the only such programs in our region, serving patients in Delaware and surrounding communities in Maryland, Pennsylvania and New Jersey. The majority of the bone-marrow and stem-cell transplants are performed on an outpatient basis. However, the bone-marrow transplant program operates a fully equipped inpatient unit for procedures requiring longer hospital stays. We can assist you and your family to find overnight accommodations when necessary.

Helen F. Graham Cancer Center & Research Institute4701 Ogletown-Stanton Road, Newark, DE 19713 directions302-623-4500

Read more:
Bone Marrow and Stem Cell Transplants ChristianaCare